Medical Access and Reimbursement in Lithuania

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Esketamine nasal spray (Spravato) is centrally authorised in the EU and is registered for supply in Lithuania as a prescription, controlled psychotropic medicinal product; its marketing-authorisation information is listed in the Lithuanian State Medicines Control Agency (VVKT) medicines registry. Access in clinical practice requires specialist prescription and supervised administration consistent with the EU/EMA prescribing restrictions. # #

Reimbursement / funding: Spravato’s EU marketing authorisation allows its placement on national markets, but pricing, reimbursement and inclusion in publicly financed treatment pathways are determined at the national level. Public reimbursement for Spravato in Lithuania is not evident in the VVKT registration entry (which documents marketing authorisation and controlled supply), and available local sources describe Spravato as a prescription, supervised product rather than one with broad routine public reimbursement; in practice, access is therefore most commonly via specialist services or private clinics that can deliver supervised dosing and monitoring. Patients and clinicians should check national reimbursement decisions or contact the VVKT and the Lithuanian National Health Insurance Fund (Sodra) for current coverage determinations. # #

Ketamine is an established, authorised medicinal product in Lithuania for anaesthesia and pain indications and is used clinically within hospitals; additionally, off‑label therapeutic ketamine (typically IV/sub‑anaesthetic infusions) is provided in specialist or private clinic settings for treatment‑resistant depression and acute suicidality in many countries and is offered in Lithuania by private providers. This clinical use is off‑label (i.e., outside of formal national antidepressant indications) and therefore reimbursement is generally not standardised—hospital uses (anaesthesia, analgesia) are part of routine funded care, whereas private ketamine infusion therapy for depression is typically self‑funded or paid via private insurance depending on the insurer and policy. # #

Clinical/regulatory nuance: because ketamine’s approved indications in Lithuania are tied to anaesthesia and acute pain, psychiatrists offering ketamine infusions for depression operate in an off‑label/legal framework requiring specialist oversight and informed consent; third‑party payor coverage for off‑label psychiatric ketamine in Lithuania is variable and typically limited. For patients seeking ketamine‑based depression care, verify whether a given clinic documents treatment protocols, clinician qualifications, and whether any portion of the care is eligible for reimbursement through Sodra or private insurers.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Ban/controls typically apply to its active components and plants containing DMT.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (This category covers synthetic phenethylamine psychedelics such as 2C‑B, 2C‑I, etc.) #